Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMAR: Dapagliflozin and Statins in HIV Patients on INSTIs with Elevated Metabolic Risk
NCT06317051Phase 3Active, not recruiting
- Sponsor
- The Kirby Institute
- Start
- Dec 2024
- Primary completion
- Jul 2026
- Modality
- Orthosteric Ligands
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial of dapagliflozin, pitavastatin, rosuvastatin and ezetimibe in human immunodeficiency virus infection (HIV) (4 arms), sponsored by The Kirby Institute. Primary endpoints: Impact of dapagliflozin vs. placebo on weight reduction at 24 weeks and Impact of pitavastatin vs. rosuvastatin/ezetimibe on low-density lipoproteins (LDL) concentration at 24 weeks. Started Dec 2024; status: active, not recruiting.
02
Drugs
dapagliflozinpitavastatinrosuvastatinezetimibe
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06317051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06317051.